WuXi Waylaid
When Congress resumes next month, the BioSecure Act will be one of its top priorities. The bill, which could dramatically reorder the global pharmaceutical supply...
China’s Ozempic Test
Novo Nordisk, the maker of Ozempic, has enjoyed a China boom in recent years, commanding 77 percent of the market. But that kind of dominance...
The Fentanyl Fix
The U.S. and China agreed to cooperate on fentanyl, but progress is proving hard to come by.
Dali Yang on the Mistakes Made In Covid’s Early Days
The political scientist and sinologist talks about the early days of the pandemic in Wuhan, and how the Chinese authorities’ lack of transparency led the...
A Crackdown Comes for Healthcare
Six months into a campaign to rout out corruption from the Chinese healthcare industry, many of the underlying issues in the sector remain unchanged.
The DNA Distortion
ANDE, a U.S. biotechnology company, promised a "faster way to a safer world" with its revolutionary rapid DNA testing machine. But by selling its innovation...
G42’s Ties To China Run Deep
More details on the Emirati technology firm at the nexus of China and the U.S.’s technological and geopolitical rivalry.
The Science Split?
With a landmark, 44-year-old agreement set to expire at the end of this month, the U.S. is facing one of its biggest China tests: Can...
The Biotech Urban Legend
Once upon a time, a U.S. company and a Chinese company developed an innovative and effective treatment for cancer. Will that ever happen again?
China’s mRNA Blockade
China had high hopes the pandemic would launch its domestic pharmaceutical industry. That didn't happen.
China’s Bill of Health
A look at the state of China’s healthcare system, including the cost of zero-Covid.
China’s Brutal COVID Winter
The precautions to reduce Covid-19 infections are simply not an option for many Chinese households.